Trientine tetrahydrochloride (TETA 4HCL) – Cuprior® for the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/08/2019|
|Rapid review completed||09/10/2019|
|Rapid Review outcome||A full HTA is not recommended.The NCPE recommends that trientine tetrahydrochloride (TETA 4HCl) not be considered for reimbursement at the submitted price|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.